TARS News and Press, Tarsus Pharmaceuticals Inc. From 05/02/22

IRVINE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with e...

TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure Webcast today at 8:00 a....

IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, will hold a webcast on Monday, May 2, 2022 at...

The following slide deck was published by Tarsus Pharmaceuticals, Inc. in conjunction with this event. For further details see: Tarsus Pharmaceuticals (TARS) Investor Presentation - Slideshow

IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data yesterday from its Atlas Conti...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blueprint Medicines (NASDAQ: BPMC ): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE: BMY ):  Food and Drug Admi...

Tarsus Pharmaceuticals press release (NASDAQ:TARS): FY GAAP EPS of -$0.67 misses by $0.10. Revenue of $57.03M beats by $7.96M. For further details see: Tarsus Pharmaceuticals GAAP EPS of -$0.67 misses by $0.10, revenue of $57.03M beats by $7.96M

Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year Advancing pipeline this year with planned Phase 2 initiations of TP-03 for Meibomian Gland Disease and TP-04 for Rosacea, and...

IRVINE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced management will present at th...

Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs IRVINE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:...